{"id":"W2907407844","doi":"10.1634/theoncologist.2018-0838","title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Weill Cornell Medical College; AstraZeneca; Genentech; Eli Lilly and Company; Agios Pharmaceuticals; Exelixis","keywords":"Medicine; Hepatocellular carcinoma; Cohort; Pharmacokinetics; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Toxicity; Gastroenterology; Phases of clinical research; Small interfering RNA; RNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002979225,0.001341364,0.00172678,0.0003441079,0.0004899619,0.0005367842,0.0007739883,0.0008200934,0.002192035],"category_scores_gemma":[0.0008324415,0.0004619206,0.0009329346,0.0003726649,0.0009701775,0.0007903926,0.0003880693,0.002900477,0.0006933589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008317335,"about_ca_system_score_gemma":0.001330944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005064703,"about_ca_topic_score_gemma":0.001025626,"domain_scores_codex":[0.9992773,0.0003455296,0.00003741148,0.000125446,0.0000749544,0.0001393614],"domain_scores_gemma":[0.99903,0.0001203186,0.0001686998,0.0001967744,0.0000921029,0.0003920693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4285121,0.2421326,0.02290302,0.0003932009,0.000856263,0.0003696719,0.0005785596,0.003096347,0.2008863,0.0003650817,0.004082307,0.09582453],"study_design_scores_gemma":[0.130463,0.8324021,0.01916378,0.00001091126,0.0002566572,0.0003300632,0.00005868241,0.001451242,0.0135774,0.0001625058,0.002093478,0.00003012507],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960062,0.0002391706,0.0008944852,0.0001143356,0.00003929987,0.001827773,0.0003724716,0.00007373478,0.0004325774],"genre_scores_gemma":[0.988753,0.0002549114,0.003383702,0.0003772527,0.00008785867,0.003735495,0.00158685,0.00003763308,0.001783401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002979225,"threshold_uncertainty_score":0.01575583,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06688128871368598,"score_gpt":0.3491842452595836,"score_spread":0.2823029565458976,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}